ReviewJournal of inflammation research2026
Nanomaterial-Based Strategies Targeting IL-1 Signalling in Inflammatory Bowel Disease: Therapeutic Applications and Mechanistic Insights.
Review in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory Bowel Disease (IBD) is a group of gastrointestinal disorders characterized by chronic relapsing inflammation, primarily comprising Ulcerative Colitis and Crohn's Disease. Interleukin(IL) -1 (IL-1) family plays a central role in the immunoregulation of IBD, where its aberrant activation amplifies inflammatory responses through nuclear factor kappa B (NF-κB) and mitogen-activated protein kinase (MAPK) pathways, leading to excessive release of pro-inflammatory cytokines, disruption of the epithelial barrier, and mucosal damage. Although biological agents targeting IL-1, such as Anakinra and the neutralizing antibody Canakinumab, have demonstrated anti-inflammatory effects in animal studies and certain clinical trials, challenges including low bioavailability, short half-life, and insufficient targeting specificity remain unresolved. In recent years, the emergence of nanomaterial technology has provided novel insights for the precise modulation of IL-1 signaling through two principal strategies. By loading IL-1 blockers or regulatory molecules into targeted and environmentally responsive nanoplatforms, it is possible to achieve site-specific drug delivery and sustained release at inflammatory loci, significantly reducing local inflammation and promoting mucosal repair. Specifically, we highlight advanced nanotechnology platforms-including lipid-based nanocarriers, polymeric nanosystems, inorganic nanomaterials, and bio-derived vesicles-that enable stimuli-responsive drug release, active mucosal targeting, and intrinsic immunomodulation to overcome biological barriers in the gut. Notably, certain active nanomaterials can directly eliminate reactive oxygen species (ROS) and block NLRP3 inflammasome activation to suppress IL-1 production. This review summarizes the role of the IL-1 family in the pathogenesis of IBD and advances in nanomaterial-based targeting strategies. Furthermore, by exploring Quality-by-Design (QbD) approaches and personalized nanocarriers, we aim to provide a new theoretical foundation and research direction for the evolution of IBD therapy toward stratified precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.